MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1

Sung Tau Chou, Hsuan Yu Peng, Kuan Chi Mo, Yuan Ming Hsu, Guan Hsun Wu, Jenn-Ren Hsiao, Su Fang Lin, Horng Dar Wang, Shine Gwo Shiah

Research output: Contribution to journalArticle

Abstract

Background: Discoidin domain receptor-1 (DDR1) tyrosine kinase is highly expressed in a variety of human cancers and involved in various steps of tumorigenesis. However, the precise mechanisms underlying the abnormal expression of DDR1 in oral squamous cell carcinoma (OSCC) has not been well investigated. Methods: The expression of DDR1 on OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Specific targeting by miRNAs was determined by software prediction, luciferase reporter assay, and correlation with target protein expression. The functions of miR-486-3p and DDR1 were accessed by MTT and Annexin V analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) and methylation specific PCR (MSP) were performed to explore the molecular mechanisms by arecoline treatment. Results: Here, we reported that DDR1 was significantly upregulated in OSCC tissues and its levels were inversely correlated with miR-486-3p expression. The experimental results in vitro confirmed that miR-486-3p decreased DDR1 expression by targeting the 3′-UTR of DDR1 mRNA. Overexpression of miR-486-3p led to growth inhibition and apoptosis induction with a similar function by knockdown of DDR1. Aberrant methylation of ANK1 promoter was a highly prevalent in OSCC and contributes to oral carcinogenesis by epigenetic silencing of ANK1 and miR-486-3p. We found that miR-486-3p can be transcriptionally co-regulated with its host gene ANK1 through epigenetic repression. DNA methylation inhibitor treatment re-expressed ANK1 and miR-486-3p. Importantly, arecoline, a major betel nut alkaloid, recruited DNMT3B binding to ANK1 promoter for DNA methylation and then attenuated the expression of miR-486-3p in OSCC. Conclusion: This study was the first to demonstrate that betel nut alkaloid may recruit DNMT3B to regulate miR-486-3p/DDR1 axis in oral cancer andmiR-486-3p and DDR1 may serve as potential therapeutic targets of oral cancer.

Original languageEnglish
Article number281
JournalJournal of Experimental and Clinical Cancer Research
Volume38
Issue number1
DOIs
Publication statusPublished - 2019 Jun 28

Fingerprint

Mouth Neoplasms
MicroRNAs
Squamous Cell Carcinoma
Neoplasms
Arecoline
Areca
DNA Methylation
Alkaloids
Methylation
Epigenetic Repression
Carcinogenesis
Discoidin Domain Receptor 1
Chromatin Immunoprecipitation
Annexin A5
3' Untranslated Regions
Luciferases
Epigenomics
Real-Time Polymerase Chain Reaction
Therapeutics
Software

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chou, Sung Tau ; Peng, Hsuan Yu ; Mo, Kuan Chi ; Hsu, Yuan Ming ; Wu, Guan Hsun ; Hsiao, Jenn-Ren ; Lin, Su Fang ; Wang, Horng Dar ; Shiah, Shine Gwo. / MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. In: Journal of Experimental and Clinical Cancer Research. 2019 ; Vol. 38, No. 1.
@article{435d5e62eef6441b9d655e7b8c156a5b,
title = "MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1",
abstract = "Background: Discoidin domain receptor-1 (DDR1) tyrosine kinase is highly expressed in a variety of human cancers and involved in various steps of tumorigenesis. However, the precise mechanisms underlying the abnormal expression of DDR1 in oral squamous cell carcinoma (OSCC) has not been well investigated. Methods: The expression of DDR1 on OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Specific targeting by miRNAs was determined by software prediction, luciferase reporter assay, and correlation with target protein expression. The functions of miR-486-3p and DDR1 were accessed by MTT and Annexin V analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) and methylation specific PCR (MSP) were performed to explore the molecular mechanisms by arecoline treatment. Results: Here, we reported that DDR1 was significantly upregulated in OSCC tissues and its levels were inversely correlated with miR-486-3p expression. The experimental results in vitro confirmed that miR-486-3p decreased DDR1 expression by targeting the 3′-UTR of DDR1 mRNA. Overexpression of miR-486-3p led to growth inhibition and apoptosis induction with a similar function by knockdown of DDR1. Aberrant methylation of ANK1 promoter was a highly prevalent in OSCC and contributes to oral carcinogenesis by epigenetic silencing of ANK1 and miR-486-3p. We found that miR-486-3p can be transcriptionally co-regulated with its host gene ANK1 through epigenetic repression. DNA methylation inhibitor treatment re-expressed ANK1 and miR-486-3p. Importantly, arecoline, a major betel nut alkaloid, recruited DNMT3B binding to ANK1 promoter for DNA methylation and then attenuated the expression of miR-486-3p in OSCC. Conclusion: This study was the first to demonstrate that betel nut alkaloid may recruit DNMT3B to regulate miR-486-3p/DDR1 axis in oral cancer andmiR-486-3p and DDR1 may serve as potential therapeutic targets of oral cancer.",
author = "Chou, {Sung Tau} and Peng, {Hsuan Yu} and Mo, {Kuan Chi} and Hsu, {Yuan Ming} and Wu, {Guan Hsun} and Jenn-Ren Hsiao and Lin, {Su Fang} and Wang, {Horng Dar} and Shiah, {Shine Gwo}",
year = "2019",
month = "6",
day = "28",
doi = "10.1186/s13046-019-1283-z",
language = "English",
volume = "38",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. / Chou, Sung Tau; Peng, Hsuan Yu; Mo, Kuan Chi; Hsu, Yuan Ming; Wu, Guan Hsun; Hsiao, Jenn-Ren; Lin, Su Fang; Wang, Horng Dar; Shiah, Shine Gwo.

In: Journal of Experimental and Clinical Cancer Research, Vol. 38, No. 1, 281, 28.06.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1

AU - Chou, Sung Tau

AU - Peng, Hsuan Yu

AU - Mo, Kuan Chi

AU - Hsu, Yuan Ming

AU - Wu, Guan Hsun

AU - Hsiao, Jenn-Ren

AU - Lin, Su Fang

AU - Wang, Horng Dar

AU - Shiah, Shine Gwo

PY - 2019/6/28

Y1 - 2019/6/28

N2 - Background: Discoidin domain receptor-1 (DDR1) tyrosine kinase is highly expressed in a variety of human cancers and involved in various steps of tumorigenesis. However, the precise mechanisms underlying the abnormal expression of DDR1 in oral squamous cell carcinoma (OSCC) has not been well investigated. Methods: The expression of DDR1 on OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Specific targeting by miRNAs was determined by software prediction, luciferase reporter assay, and correlation with target protein expression. The functions of miR-486-3p and DDR1 were accessed by MTT and Annexin V analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) and methylation specific PCR (MSP) were performed to explore the molecular mechanisms by arecoline treatment. Results: Here, we reported that DDR1 was significantly upregulated in OSCC tissues and its levels were inversely correlated with miR-486-3p expression. The experimental results in vitro confirmed that miR-486-3p decreased DDR1 expression by targeting the 3′-UTR of DDR1 mRNA. Overexpression of miR-486-3p led to growth inhibition and apoptosis induction with a similar function by knockdown of DDR1. Aberrant methylation of ANK1 promoter was a highly prevalent in OSCC and contributes to oral carcinogenesis by epigenetic silencing of ANK1 and miR-486-3p. We found that miR-486-3p can be transcriptionally co-regulated with its host gene ANK1 through epigenetic repression. DNA methylation inhibitor treatment re-expressed ANK1 and miR-486-3p. Importantly, arecoline, a major betel nut alkaloid, recruited DNMT3B binding to ANK1 promoter for DNA methylation and then attenuated the expression of miR-486-3p in OSCC. Conclusion: This study was the first to demonstrate that betel nut alkaloid may recruit DNMT3B to regulate miR-486-3p/DDR1 axis in oral cancer andmiR-486-3p and DDR1 may serve as potential therapeutic targets of oral cancer.

AB - Background: Discoidin domain receptor-1 (DDR1) tyrosine kinase is highly expressed in a variety of human cancers and involved in various steps of tumorigenesis. However, the precise mechanisms underlying the abnormal expression of DDR1 in oral squamous cell carcinoma (OSCC) has not been well investigated. Methods: The expression of DDR1 on OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Specific targeting by miRNAs was determined by software prediction, luciferase reporter assay, and correlation with target protein expression. The functions of miR-486-3p and DDR1 were accessed by MTT and Annexin V analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) and methylation specific PCR (MSP) were performed to explore the molecular mechanisms by arecoline treatment. Results: Here, we reported that DDR1 was significantly upregulated in OSCC tissues and its levels were inversely correlated with miR-486-3p expression. The experimental results in vitro confirmed that miR-486-3p decreased DDR1 expression by targeting the 3′-UTR of DDR1 mRNA. Overexpression of miR-486-3p led to growth inhibition and apoptosis induction with a similar function by knockdown of DDR1. Aberrant methylation of ANK1 promoter was a highly prevalent in OSCC and contributes to oral carcinogenesis by epigenetic silencing of ANK1 and miR-486-3p. We found that miR-486-3p can be transcriptionally co-regulated with its host gene ANK1 through epigenetic repression. DNA methylation inhibitor treatment re-expressed ANK1 and miR-486-3p. Importantly, arecoline, a major betel nut alkaloid, recruited DNMT3B binding to ANK1 promoter for DNA methylation and then attenuated the expression of miR-486-3p in OSCC. Conclusion: This study was the first to demonstrate that betel nut alkaloid may recruit DNMT3B to regulate miR-486-3p/DDR1 axis in oral cancer andmiR-486-3p and DDR1 may serve as potential therapeutic targets of oral cancer.

UR - http://www.scopus.com/inward/record.url?scp=85068144471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068144471&partnerID=8YFLogxK

U2 - 10.1186/s13046-019-1283-z

DO - 10.1186/s13046-019-1283-z

M3 - Article

C2 - 31253192

AN - SCOPUS:85068144471

VL - 38

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 281

ER -